Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (March 2019)
36 slides from Prescient Therapeutics's investor presentation, Mar 25, 2019
Slide 1: Capital Raising Presentation March 2019
For personal use only CAPITAL RAISING PRESENTATION MARCH 2019 Prescient Therapeutics Limited (ASX: PTX) March 2019 NOT FOR RELEASE TO U.S. WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES EXCEPT TO APPROVED U.S. INVESTORS
Slide 2: Disclaimer and Safe Harbor: Forward-looking statements
DISCLAIMER AND SAFE HARBOR For personal use only Forward-looking statements Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements
Slide 3: Disclaimer and Safe Harbor: Summary information
DISCLAIMER AND SAFE HARBOR For personal use only Summary information This document may not contain all the details and information necessary for you to make a decision or evaluation. This document contains summary information about the Company and its activities which is current only as at the date
Slide 4: Disclaimer and Safe Harbor: Participation in the Offer
DISCLAIMER AND SAFE HARBOR For personal use only Participation in the Offer Determination of eligibility of investors for the purposes of the Capital Raising will be by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discreti
Slide 5: Disclaimer and Safe Harbor: Not financial product advice
DISCLAIMER AND SAFE HARBOR For personal use only Not financial product or investment advice This document is not financial product or investment advice, a recommendation to participate in the Capital Riasing or accounting, legal or tax advice. It has been prepared without taking into account the obj
Slide 6: Executive Summary
EXECUTIVE SUMMARY For personal use only Prescient Therapeutics Ltd (ASX:PTX) is an ASX-listed biotechnology company focused on novel targeted (precision) cancer therapies, overcoming limitations of previous approaches to problematic pathways • 4 clinical programs in oncology: • Company is raising A$
Slide 7: Clinical Pipeline
CLINICAL PIPELINE For personal use only • Deep clinical pipeline with 4 data readouts expected in the next 18 months DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHASE 3 BREAST CANCER PTX-200 (Ph2 pt1 readout Q4 2019) AML PTX-200 (Ph1b readout Q3/Q4 2019) OVARIAN PTX-200 (Ph1b readout Q
Slide 8: Expected Newsflow & Share Price Catalysts
EXPECTED NEWSFLOW & SHARE PRICE CATALYSTS For personal use only • Q2 2019 Commencement of Ph1b PTX-100 • Q3/Q4 2019 Phase 1b PTX-200 results in expanded cohort AML • Q4 2019 Phase 1b PTX-200 results in ovarian cancer • Q4 2019 Phase 2 (part1) PTX-200 results in breast cancer • Q2 2020 Phase 1b PTX-1
Slide 9: Corporate Snapshot
CORPORATE SNAPSHOT KEY METRICS For personal use only ASX Ticker PTX Market Capitalisation1 A$12.1 M (US$8.6 M) Total Issued Capital 211.8 M shares Pro Forma Cash Position2 A$10.3 M (US$7.3 M) Options 57.8 M Top 20 Own 52% Share Price1 A$0.058 (US$0.041) 6 month turnover3 41.0 M shares; A$3.7 M (US$2
Slide 10: Achievements Since Last Capital Raising
ACHIEVEMENTS SINCE LAST CAPITAL RAISING For personal use only • Since raising $10m in May 2016, the Company has achieved significant milestones whilst being prudent with its cash balance (still $3.3m remaining) May 2016 Now • Ph 1b completed. Achieved encouraging efficacy signal over • Breast cancer
Slide 11: Board of Directors
BOARD OF DIRECTORS For personal use only • Experienced; complementary & collaborative Steven • 16 years’ experience in healthcare investment banking Yatomi-Clarke • Collaborator on clinical trials conducted in Australia and the US in cancer immunotherapy CEO & Managing Director • BSc (Hons, Biochemi
Slide 12: First Class Development Team With Proven Track Record
FIRST CLASS DEVELOPMENT TEAM WITH PROVEN TRACK RECORD • Proven success from discovery and clinical development, through to FDA approvals For personal use only • Professor and Chair, Department of Drug Discovery - Moffitt Cancer Center Said Sebti, PhD • Co-inventor of PTX-100 & PTX-200 Chief Scientif
Slide 13: PTX-200
PTX-200 For personal use only FIRST IN CLASS PH DOMAIN INHIBITOR WITH NOVEL AKT INHIBITION Breast cancer AML Ovarian cancer 13 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 14: PTX-200: First in Class PH Domain Inhibitor Leading to Novel Akt Inhibition
PTX-200 FIRST IN CLASS PH DOMAIN INHIBITOR LEADING TO NOVEL AKT INHIBITION For personal use only • Akt activation inhibitor that is highly selective for killing tumors with hyperactivated Akt PTX-200 (TCN-P) • Novel mechanism of action • Inhibits Akt without the toxicity of other attempts • Anti-pro
Slide 15: PTX-200: Novel PH Domain Inhibition to Inactivate Akt
PTX-200: NOVEL PH DOMAIN INHIBITION TO INACTIVE AKT For personal use only • PTX-200 binds to PH domains to inactivate, inter alia, Akt. » Mimics the phosphate of the natural ligand for the PH domain, PIP3 » By binding to the PH domain, PTX-200 prevents binding to the plasma membrane, thus inhibiting
Slide 16: HER2- Breast Cancer Overview
HER2 - BREAST CANCER OVERVIEW For personal use only 80% OF BREAST CANCERS ARE HER2- BUT THIS IS STILL UNDERSERVED BY NEW DRUGS $10.6B MARKET NEED: $5.4B LACK OF PIPELINE AGENTS ADDRESSING » RESISTANT ER+ DISEASE » NEOADJUVANT THERAPY 41% Generics 2015 2025 PTX’S NICHE: NEOADJUVANT » AKT IS ADVERSE P
Slide 17: Roche's Ipatasertib: Validating Akt Inhibition in Breast Cancer
ROCHE’S IPATASERTIB: VALIDATING AKT INHIBITION IN BREAST CANCER 1. The PI3K/Akt survival pathway is 2. Akt inhibitors enhance the killing of For personal use only activated in response to chemotherapy breast cancer cells (~2 fold) 3. …and Akt inhibition leads to clinical benefit 17 PRESENTED BY REBE
Slide 18: What Does Success Look Like for This Disease?
WHAT DOES SUCCESS LOOK LIKE FOR THIS DISEASE? For personal use only • Studies on all sub-types of locally advanced breast cancer receiving weekly chemo reports a wide range of pCR (8-28%) • For women with locally advanced ER+, HER2 negative breast cancer, typical expectations are: » pCR of 16% (11-2
Slide 19: PTX-200 Breast Cancer Now in Phase 2a
PTX-200 BREAST CANCER NOW IN PHASE 2A For personal use only • PTX-200 35 mg/m2 in combination with paclitaxel, followed by AC (doxorubicin & cyclophosphamide) for neoadjuvant therapy • Patients with locally advanced HER2- breast cancer Joseph Sparano, M.D. Principal Investigator • 5 patients from Ph
Slide 20: Phase 1b Efficacy Results Very Encouraging
PHASE 1B EFFICACY RESULTS VERY ENCOURAGING For personal use only Metastatic & locally advanced patients Locally advanced patients ER+ Triple Total ER+ Triple Total negative negative pCR/CR 2 0 2 pCR/CR 2 0 2 PR 1 2 3 PR 1 2 3 SD 1 2 3 SD 0 0 0 PD 0 2 2 PD 0 0 0 ORR 75% 33% 50% ORR 100% Visual repres
Slide 21: No Progression After Months
NO PROGRESSION AFTER 27 MONTHS For personal use only • Typically, up to 60% of patients with locally advanced breast cancer will recur by 5 years, the majority of them within the first 2 years. • All clinical responses seen so far (in locally advanced population counting towards Phase 2 analysis) ha
Slide 22: Biomarker ZNF217 Prognostic of Poor Survival and Predictive of Response
BIOMARKER ZNF217 IS PROGNOSTIC OF POOR SURVIVAL AND PREDICTIVE OF RESPONSE TO PTX-200 For personal use only • ZNF217 overexpressed in 30% of breast and other cancers • Associated with » Metastasis » Resistance to chemotherapy » Poor survival • ZNF217 expression is positively correlated with ER expre
Slide 23: PTX-200 in AML – Executive Summary
PTX-200 IN AML – EXECUTIVE SUMMARY For personal use only • Akt is highly relevant in AML • PTX-200 address the “phenotype, not the genotype” in AML mutations • Like other recent successful strategies in AML, PTX-200 is a targeted therapy complementing a “backbone” of standard chemotherapy • PTX-200
Slide 24: Phase 1b Trial Underway: Acute Myeloid Leukemia
PHASE 1B TRIAL UNDERWAY: ACUTE MYELOID LEUKEMIA For personal use only • Phase 1 results with PTX-200 (monotherapy) very encouraging • Now PTX-200 + cytarabine in refractory or relapsed acute leukemia • Professor Jeff Lancet at Moffitt Cancer Center leading the trial Jeffrey E Lancet, M.D. • Yale Can
Slide 25: Phase 1b Ovarian Cancer Trial
PHASE 1B OVARIAN CANCER TRIAL For personal use only • Significant need for new products to treat platinum-resistant ovarian cancer • High pAkt contributes to platinum resistance • PTX-200 already proven overcome cisplatin resistance and synergize with cisplatin in pre-clinical studies Robert Wenham,
Slide 26: PTX-100
PTX-100 For personal use only PHASE 1 IN SOLID TUMORS COMPLETED NOW PURSUING A TRANSFORMATIVE OPPORTUNITY IN RAS & RHO MUTANT CANCERS 26 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 27: PTX-100: First in Class, First in Man GGT-1 Inhibitor of Ras Pathway
PTX-100 FIRST IN CLASS, FIRST IN MAN GGT-1 INHIBITOR OF RAS PATHWAY For personal use only • Inhibitor of the GGT-1 enzyme PTX-100 (GGTI-2418) • Invented at Yale University and Moffitt Cancer Center • Single agent activity in mouse models of various cancers • Combination therapy is also very effectiv
Slide 28: Ras Pathway Is an Important but Elusive Target
RAS PATHWAY IS AN IMPORTANT BUT ELUSIVE TARGET For personal use only GROWTH FACTOR • Ras mutated in 30% of all human cancers and 90% RECEPTOR TYR KINASE in certain cancers » A staggering 3 million new cancers diagnosed worldwide Grb2 SoS each year with Ras mutations Ras FGTI • Mutant Ras tumors are
Slide 29: RhoA Mutations Play a Prominent Role in TCL Pathogenesis
RHOA MUTATIONS PLAY A PROMINENT ROLE IN TCL PATHOGENESIS For personal use only Schematic of RhoA protein structure, with alterations • RhoA G17V mutation is a driver of pathogenesis of AITL, PTCL-NOS • Other RhoA mutations driver a number of other malignancies • PTX-100 a pan RhoA inhibitor regardle
Slide 30: PTX-100 the Only Drug Targeting RhoA
PTX-100 THE ONLY DRUG TARGETING RHOA • PTX-100 has a unique position in RhoA mutant For personal use only malignancies » Only clinical stage RhoA inhibitor globally • Phase 1 trial in solid tumours completed – safety profile Unmet clinical need established • Basket PK/PD study expected to begin in Q
Slide 31: Case Study – Loxo Oncology
CASE STUDY – LOXO ONCOLOGY (NASDAQ:LOXO) • Lead drug Larotrectnib: targeted therapy for cancers with TRK fusions For personal use only • An unmet need in small patient population (2,500-3,000 cases/year in US) • Pioneered “one trial to launch” basket study • Only 4 years from initiating Phase 1 2014
Slide 32: Capital Raising
CAPITAL RAISING For personal use only 32 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 33: Capital Raising Summary
CAPITAL RAISING SUMMARY • Prescient is conducting a A$9.1m capital raising that will fund the Company’s clinical programs over the next 18 months: For personal use only » PTX-100 Basket PK/PD trial » PTX-200 clinical trials » General working capital • Offer price of A$0.05 per share represents a 13.
Slide 34: Indicative Timetable
INDICATIVE TIMETABLE For personal use only Trading halt Thursday 21st March 2019 Offer announced, lodge Entitlement Offer Prospectus with ASX and company Monday, 25th March 2019 resumes trading “Ex” date for Entitlement Offer Thursday, 28th March 2019 Record date for Entitlement Offer Friday, 29th M
Slide 35: Key Specific Risks
KEY SPECIFIC RISKS Key specific risks include, but are not limited to: For personal use only • The nature of drug development is inherently risky, with many drug candidates failing to be successfully developed into marketable products. Prescient’s clinical trials may fail to meet their desired endpo
Slide 36: Contact
For personal use only CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com 36 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Prescient Therapeutics — Investor Presentation (March 2019) on 6ix